Browse

Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis

Cited 48 time in Web of Science Cited 50 time in Scopus
Authors
Han, Seung Hyeok; Choi, Sung Hee; Cho, Bong Jun; Lee, Yenna; Park, Young Joo; Lee, Hong Kyu; Han, Dae Suk; Jang, Hak C.; Park, Kyong Soo; Kim, Young-Bum; Kang, Shin-Wook; Moon, Min Kyung; Lim, Soo
Issue Date
2010-11
Publisher
W B SAUNDERS CO-ELSEVIER INC
Citation
METABOLISM-CLINICAL AND EXPERIMENTAL; Vol.59 11; 1656-1662
Abstract
Fibroblast growth factor-21 (FGF-21) is a new metabolic regulator, which is related to antiobesity and insulin sensitivity in vivo. However, the clinical implication of FGF-21 is poorly understood. To investigate whether FGF-21 may play a role as a metabolic regulator in patients with end-stage renal disease, we measured serum concentrations of FGF-21, inflammatory markers, and metabolic parameters in healthy people (n = 63) and nondiabetic patients receiving peritoneal dialysis (PD, n = 72). The patients were treated with angiotensin receptor blocker for 6 months, and the changes in FGF-21 concentration and metabolic parameters were assessed. Compared with controls, serum FGF-21 concentration was 8 times higher in patients undergoing PD (754.2 +/- 463.5 vs 86.9 +/- 60.2 pg/mL, P < .001). In controls, only lipid parameters correlated positively with FGF-21 concentration. In contrast, inflammatory markers (interleukin-6, fibrinogen, high-sensitivity C-reactive protein) and homeostasis model assessment of insulin resistance (HOMA-IR) correlated positively and residual renal function correlated inversely with serum FGF-21 concentration in PD patients. In a multivariate analysis adjusting these factors, residual renal function, HOMA-IR, and fibrinogen concentration were independent determinants of serum FGF-21 concentration. After 6-month angiotensin receptor blocker treatment, serum FGF-21 concentration declined significantly by 13% and HOMA-IR and inflammatory markers improved in PD patients. These findings suggest that FGF-21 may play a role in insulin resistance in patients with end-stage renal disease. (C) 2010 Elsevier Inc. All rights reserved.
ISSN
0026-0495
Language
English
URI
https://hdl.handle.net/10371/77650
DOI
https://doi.org/10.1016/j.metabol.2010.03.018
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse